Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Role of Glutamatergic Function in the Pathophysiology of Treatment-resistant Schizophrenia

NCT06270108 is registered in ClinicalTrials.gov with King's College London as lead sponsor.

NCT NCT06270108
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06270108 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Role of Glutamatergic Function in the Pathophysiology of Treatment-resistant Schizophrenia
Lead sponsor
King's College London
Phase
Phase 1
Overall status
Unknown status
Start date
November 14, 2022
Completion date
December 31, 2024
Enrollment
288 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy controls, treatment-resistant schizophrenia, treatment-responsive schizophrenia